Why the study?
Does intravenous or subcutaneous pimobendan improve hemodynamic parameters in healthy dogs?
Does intravenous or subcutaneous pimobendan improve hemodynamic parameters in healthy dogs?
A single intravenous dose of pimobendan (0.15 mg/kg) induces rapid positive inotropic effects and decreases LVEDP in healthy dogs, whereas subcutaneous administration has no acute hemodynamic effects.
No immediate change to canine HF management; leaves open translation of rapid inotropic effects to clinical cases.
We investigated the effects of an injectable pimobendan solution (0.15 mg/kg) on cardiac function in healthy dogs. Fifteen dogs were divided into placebo, intravenous pimobendan injection, and subcutaneous pimobendan injection groups. In the placebo, the heart rate, systolic and end-diastolic left ventricular pressure (LVPs and LVEDP), and peak positive (max dP/dt) and negative (min dP/dt) first derivatives of the left ventricular pressure did not change for 60 min. After the intravenous pimobendan injection, LVEDP decreased significantly within 5 min, while the max dP/dt increased, and the effects continued until 60 min. In comparison, there were no hemodynamic changes after the subcutaneous pimobendan injection. This study demonstrates that injectable pimobendan induced a rapid inotropic effect and decreased the LVEDP in dogs.
No takes yet. Share an insight, caveat, or question.
Hori et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: